← Back to patent-cliff list
CAS 149353-84-4
4-(Piperidin-4-yl)benzoic acid hydrogen chloride
Codes: (XXIII)859946-1-b
Application context (from source-drug indications)
Biliary tract cancerTasurgratinibBile duct cancerTasurgratinibSolid tumourTasurgratinibCholangiocarcinomaTasurgratinibBreast cancerTasurgratinibHepatic function declineTasurgratinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Tasurgratinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]benzoic acid→4-Phenylpiperidine→1-(4-Phenylpiperidin-1-yl)ethan-1-one→4-(1-Acetylpiperidin-4-yl)benzoic acid→4-(Piperidin-4-yl)benzoic acid hydrogen chloride→N-Boc-4-(4-bromophenyl)piperidine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.